| Literature DB >> 36018584 |
Feargal J Ryan1,2, Yuefang Ma2, Liam M Ashander2, Michael Kvopka2, Binoy Appukuttan2, David J Lynn1,2, Justine R Smith2.
Abstract
Purpose: Molecular profiling of human retinal endothelial cells provides opportunities to understand the roles of this cell population in maintenance of the blood-ocular barrier, and its involvements in diverse retinal vasculopathies. We aimed to generate a transcriptome of human retinal endothelial cells in the unstimulated state, and following treatment with inflammatory cytokines linked to cell dysfunction.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36018584 PMCID: PMC9428361 DOI: 10.1167/tvst.11.8.27
Source DB: PubMed Journal: Transl Vis Sci Technol ISSN: 2164-2591 Impact factor: 3.048
Description of Human Retinal Endothelial Samples, Including Donor Demographics and Alignment Statistics
| Isolate (Passage) | Donor: Sex, Age | Death to Isolation Time | Condition: Cytokine, Time | Paired Reads | Paired Reads Aligning to Genome (%) | Paired Reads Aligning Unambiguously to Annotated Genes (%) |
|---|---|---|---|---|---|---|
| 1 (2) | F, 42 yr | 20 hr | Control, 60 min | 91,880,923 | 91,228,568 (99.29%) | 50,592,086 (55.06%) |
| Control, 24 hr | 58,665,969 | 58,425,439 (99.59%) | 35,353,899 (60.26%) | |||
| IL-1β, 60 min | 54,392,166 | 54,185,476 (99.62%) | 32,791,528 (60.29%) | |||
| IL-1β, 24 hr | 61,284,640 | 60,996,602 (99.53%) | 38,127,340 (62.21%) | |||
| TNF-α, 60 min | 58,674,151 | 58,451,189 (99.62%) | 40,374,450 (68.81%) | |||
| TNF-α, 24 hr | 43,937,185 | 43,629,625 (99.30%) | 24,876,879 (56.62%) | |||
| 2 (2) | F, 59 yr | 10 hr | Control, 60 min | 57,203,198 | 56,831,377 (99.35%) | 39,232,816 (68.59%) |
| Control, 24 hr | 57,061,723 | 56,662,291 (99.30%) | 36,704,318 (64.32%) | |||
| IL-1β, 60 min | 67,527,485 | 67,270,881 (99.62%) | 43,837,000 (64.92%) | |||
| IL-1β, 24 hr | 54,150,960 | 53,934,356 (99.60%) | 35,183,316 (64.97%) | |||
| TNF-α, 60 min | 59,448,395 | 59,204,657 (99.59%) | 34,291,555 (57.68%) | |||
| TNF-α, 24 hr | 44,707,449 | 43,706,002 (97.76%) | 28,200,494 (63.08%) | |||
| 3 (3) | F, 43 yr | 24 hr | Control, 60 min | 57,916,040 | 57,695,959 (99.62%) | 38,687,922 (66.80%) |
| Control, 24 hr | 50,261,528 | 50,045,403 (99.57%) | 33,012,471 (65.68%) | |||
| IL-1β, 60 min | 66,313,255 | 65,968,426 (99.48%) | 41,168,092 (62.08%) | |||
| IL-1β, 24 hr | 50,499,562 | 50,247,064 (99.50%) | 32,402,699 (64.16%) | |||
| TNF-α, 60 min | 60,050,927 | 59,978,866 (99.88%) | 9,897,383 (16.48%) | |||
| TNF-α, 24 hr | 50,292,931 | 50,031,408 (99.48%) | 31,064,967 (61.77%) | |||
| 4 (2) | F, 54 yr | 31 hr | Control, 60 min | 55,981,156 | 55,757,231 (99.60%) | 37,892,323 (67.69%) |
| Control, 24 hr | 54,062,301 | 53,802,802 (99.52%) | 33,214,431 (61.44%) | |||
| IL-1β, 60 min | 63,682,704 | 63,427,973 (99.60%) | 34,960,173 (54.90%) | |||
| IL-1β, 24 hr | 48,600,754 | 48,391,771 (99.57%) | 31,419,265 (64.65%) | |||
| TNF-α, 60 min | 60,328,580 | 59,791,656 (99.11%) | 33,880,535 (56.16%) | |||
| TNF-α, 24 hr | 72,695,997 | 72,019,924 (99.07%) | 46,217,221 (63.58%) | |||
| 5 (2) | F, 59 yr | 18 hr | Control, 60 min | 51,457,569 | 51,236,301 (99.57%) | 34,115,169 (66.30%) |
| Control, 24 hr | 48,618,962 | 48,385,591 (99.52%) | 33,696,362 (69.31%) | |||
| IL-1β, 60 min | 60,230,290 | 60,079,714 (99.75%) | 13,097,586 (21.75%) | |||
| IL-1β, 24 hr | 49,383,724 | 49,126,929 (99.48%) | 32,349,949 (65.51%) | |||
| TNF-α, 60 min | 55,171,735 | 54,796,567 (99.32%) | 35,131,641 (63.68%) | |||
| TNF-α, 24 hr | 47,890,187 | 47,636,369 (99.47%) | 30,255,012 (63.18%) |
Abbreviations: F = female, IL-1β = interleukin-1β, TNF-α = tumor necrosis factor-α, yr = years, min = minutes, hr = hours.
Figure 1.Technical validations of the transcriptomic dataset generated for human retinal endothelial cells treated with interleukin (IL)-1β or tumor necrosis factor (TNF)-α. (A and B). Graphs showing relative transcript expression for intercellular adhesion molecule (ICAM)-1 in cytokine-treated cells after (A) 60 minutes and (B) 24 hours in comparison to medium control by RT-qPCR. Reference gene is ribosomal protein lateral stalk subunit P0 (RPLP0). (C and D). Graphs showing ICAM-1 transcript expression by RNA-sequencing for the same samples. Each circle represents one individual isolate, with crossbars indicating mean. n = 5 isolates /condition. Data were analyzed by Friedman test. (E). Bar plot representing RNA composition of medium control and cytokine-treated cells, as classified by Kraken against the NCBI RefSeq database. (F and G). Multidimensional scaling plots showing global gene expression in medium control and cytokine-treated cells (F) pre- and (G) post-adjustment for donor effect with ComBat in svaseq. Colors indicate individual isolates; shapes indicate treatments; open shapes indicate 60-minute treatments and closed shapes indicate 24-hour treatments; circles represent groupings based on individual isolates. Additional abbreviations: C = control; T = TNF-α; I = IL-1β; PC = principal component; min = minutes; hr = hours.
Expression of Selected Retinal Endothelial Cell Transcripts Under Control (no Treatment) Conditions in This Study and a Comparable RNA-Sequencing Study. Transcripts Are Identified by Gene Name, and Expression is Presented Relative to Ribosomal Protein Lateral Stalk Subunit P0 (RPLP0, ENSG00000089157)
| Mean Normalized Expression | ||
|---|---|---|
| Transcript* |
|
|
| VWF | 1.143915 | 1.800747 |
| PECAM1 | 1.118422 | 1.620269 |
| ICAM1 | 0.747052 | 0.275639 |
| VCAM1 | 0.5047 | 0.483821 |
| ALCAM | 0.850183 | 6.058259 |
| SELE | 0.504707 | 0.660358 |
| CDH5 | 1.035694 | 0.736351 |
| FLT1 | 0.777363 | 1.506564 |
| KDR | 0.968024 | 1.161705 |
| FLT4 | 0.604592 | 1.149256 |
| TIE1 | 0.857932 | 0.772019 |
| TEK | 0.713154 | 0.754045 |
| IGF1R | 0.52761 | 0.622734 |
| FGFR1 | 0.620695 | 1.563234 |
| EGFR | 0.484111 | 12.52205 |
Abbreviations: VWF = von Willebrand factor, PECAM1 = platelet and endothelial cell adhesion molecule 1, ICAM1 = intercellular adhesion molecule 1, VCAM1 = vascular cell adhesion molecule 1, ALCAM = activated leukocyte cell adhesion molecule, SELE = selectin E, CDH5 = cadherin 5, FLT1 = fms related receptor tyrosine kinase°1, KDR = kinase insert domain receptor, FLT4 = fms related receptor tyrosine kinase 4, TIE1 = tyrosine kinase with immunoglobulin like and EGF like domains°1, TEK = TEK receptor tyrosine kinase, IGF1R = insulin like growth factor 1 receptor, FGFR1 = fibroblast growth factor receptor 1, EGFR = epidermal growth factor receptor.